Related references
Note: Only part of the references are listed.ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects
Andreas Sturm et al.
JOURNAL OF CROHNS & COLITIS (2019)
Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy
Chao Chen et al.
INFLAMMATORY BOWEL DISEASES (2019)
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience
Lieven Pouillon et al.
INFLAMMATORY BOWEL DISEASES (2019)
ACG Clinical Guideline: Ulcerative Colitis in Adults
David T. Rubin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Choon Jin Ooi et al.
INTESTINAL RESEARCH (2019)
Current new challenges in the management of ulcerative colitis
Tomohiro Fukuda et al.
INTESTINAL RESEARCH (2019)
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis
S. Bonovas et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Second Korean guidelines for the management of ulcerative colitis
Chang Hwan Choi et al.
INTESTINAL RESEARCH (2017)
Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis
S. Singh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
Pawel Kawalec et al.
ARCHIVES OF MEDICAL SCIENCE (2016)
Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States
William J. Sandborn et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge
Julia Salleron et al.
JOURNAL OF CROHNS & COLITIS (2016)
Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis
Adrian D. Vickers et al.
PLOS ONE (2016)
C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis
Mahmoud H. Mosli et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
L. Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Biomarkers of Inflammation in Inflammatory Bowel Disease
Bruce E. Sands
GASTROENTEROLOGY (2015)
Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease
X. Roblin et al.
JOURNAL OF CROHNS & COLITIS (2015)
Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)
Inger Camilla Solberg et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study
Katrine Risager Christensen et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis
R. W. Stidham et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Biological Agents for Moderately to Severely Active Ulcerative Colitis A Systematic Review and Network Meta-analysis
Silvio Danese et al.
ANNALS OF INTERNAL MEDICINE (2014)
Correlations of C-reactive Protein Levels and Erythrocyte Sedimentation Rates with Endoscopic Activity Indices in Patients with Ulcerative Colitis
Jin Young Yoon et al.
DIGESTIVE DISEASES AND SCIENCES (2014)
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: An indirect treatment comparison meta-analysis
Kristian Thorlund et al.
JOURNAL OF CROHNS & COLITIS (2014)
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
Christina Ha et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Response to biologic therapy in Crohn's disease is improved with early treatment: An analysis of health claims data
David T. Rubin et al.
INFLAMMATORY BOWEL DISEASES (2012)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
A Systematic Prospective Comparison of Noninvasive Disease Activity Indices in Ulcerative Colitis
Dan Turner et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Medication compliance and persistence: Terminology and definitions
Joyce A. Cramer et al.
VALUE IN HEALTH (2008)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
